Is health politics different?

Annual Review of Political Science

Volumn 15, Issue , 2012, Pages 287-311

  Carpenter, Daniel ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

approval regulation; illness and identity politics; inequality; licensure; moral politics; social policy

Indexed keywords

EID: 84861422771     PISSN: 10942939     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-polisci-050409-113009     Document Type: Review

References (71)

1. Abbott A. 1988. The System of Professions: An Essay on the Division of Expert Labor. Chicago: Univ. Chicago
2. Press Armstrong E, Carpenter D, HojnackiM. 2006. Whose deaths matter? J. Health Polit. Policy Law 31(4):729-72
3. Baker T. 2005. The Medical Malpractice Myth. Chicago: Univ. Chicago Press
4. Blumenthal D, Morone J. 2009. The Heart of Power: Health and Politics in the Oval Office. Berkeley: Univ. Calif. Press
5. Brandt A. 2007. The Cigarette Century: The Rise, Fall and History of the Deadly Product that Defined America. New York: Basic Books
6. Campbell AL. 2004. How Policies Make Citizens. Princeton, NJ: Princeton Univ. Press
7. Carpenter D. 2002. Groups, the media, agency waiting costs, and FDA drug approval. Am. J. Polit. Sci. 46(2):490-505
8. Carpenter D. 2004. Protection without capture: product approval by a politically responsive, learning regulator. Am. Polit. Sci. Rev. 98(4):613-31
9. Carpenter D. 2010. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton, NJ: Princeton Univ. Press
10. Carpenter D, Ting MM. 2007. Regulatory errors with endogenous agendas. Am. J. Polit. Sci. 51(4):835-52
11. Chapin CF. 2010. The American Medical Association, Health Insurance Association of America, and creation of the corporate health care system. Stud. Am. Polit. Dev. 24:143-67
12. Cohen A, Hanft RS. 2004. Technology in American Health Care: Policy Directions for Effective Evaluation and Management. Ann Arbor: Univ. Mich. Press
13. Cohen C. 1999. The Boundaries of Blackness: AIDS and the Breakdown of Black Politics. Chicago: Univ. Chicago Press
14. Colby DC, Cook TC. 1991. Epidemics and agendas: the politics of nightly news coverage of AIDS. J. Health Polit. Policy Law 16(2):215-50
15. Daemmrich A. 2004. Pharmacopolitics: Drug Regulation in the United States and Germany. Chapel Hill: Univ. North Carolina Press
16. Daniels N. 2001. Justice, health, and healthcare. Am. J. Bioethics 1(2):2-16
17. Derthick M. 2002. Up in Smoke: From Legislation to Litigation in Tobacco Politics.Washington, DC: Congr. Q. Press
18. Dewan S, Ettlinger M. 2009. Comparing Public Spending and Priorities Across OECD Countries. Washington, DC: Cent. Am. Progress
19. Epstein S. 1998. Impure Science: AIDS, Activism and the Politics of Knowledge. Chicago: Univ. Chicago Press
20. Epstein S. 2007. Inclusion: The Politics of Difference in Medical Research. Chicago: Univ. Chicago Press
21. European Commission. 2007. Health and long-term care in the European Union. Special Eurobarometer 283, Dec. http://ec.europa.eu/public-opinion/ archives/ebs/ebs-283-en.pdf, QA4.1-QA4.6 and QA5.1- QA5.6, pp. 176-187
22. Fox DM. 2010. The Convergence of Science and Governance: Research, Health Policy, and American States. Berkeley: Univ. Calif. Press
23. Freidson E. 1988. Professional Powers:AStudy of Institutionalization of Formal Knowledge.Chicago: Univ.Chicago Press
24. Greenberg DS. 1998. Disease lobbies. Washington Post, Oct. 27, p. A23
25. Greene JA. 2007. Prescribing by Numbers. Baltimore, MD: Johns Hopkins Univ. Press
26. Grogan CM, Gusmano MK. 2007. Healthy Voices/Unhealthy Silence: Advocacy and Health Policy for the Poor. Washington, DC: Georgetown Univ. Press
27. Hacker JS. 1998. The historical logic of national health insurance: structure and sequence in the development of British, Canadian, and US medical policy. Stud. Am. Polit. Dev. 12(1):57-130
28. Hacker JS. 2002. The Divided Welfare State: The Battle over Public and Private Social Benefits in the United States. Cambridge, UK: Cambridge Univ. Press
29. Hacker JS. 2004. Privatizing risk without privatizing the welfare state: the hidden politics of social policy retrenchment in the United States. Am. Polit. Sci. Rev. 98(2):243-60
30. Hacker JS. 2009. The case for public plan choice in national health reform: key to cost control and quality coverage. Work. pap., Inst. America's Future, Cent.HealthEcon. Family Sec., School of Law, Univ.Calif. Berkeley. http://institute.ourfuture.org/files/Jacob-Hacker-Public-Plan-Choice.pdf
31. Hacker JS, Pierson P. 2011. Drift and democracy: the neglected politics of policy inaction. Unpublished manuscript, Dep. Polit. Sci., Yale Univ.
32. Hall RL, Deardorff AV. 2006. Lobbying as legislative subsidy. Am. Polit. Sci. Rev. 100:69-84
33. Hegde D, Mowery DC. 2008. Politics and funding in the US public biomedical R&D system. Science 322(5909):1797-98
34. Herzlinger RA. 2004. Consumer-Driven Health Care: Implications for Providers, Payers, and Policymakers. San Francisco: Jossey-Bass
35. Huber E, Stephens JD. 2001. Development and Crisis of the Welfare State. Chicago: Univ. Chicago Press
36. Huber JC, Shipan, Pfahler M. 2001. Legislatures and statutory control of bureaucracy. Am. J. Polit. Sci. 45(2):330-45
37. Immergut E. 1992. Health Politics: Interests and Institutions in Western Europe. New York: Cambridge Univ. Press
38. Jacobs LR. 1995. The politics of America's supply state: health reform and medical technology. Health Aff. 14(2):143-57
39. Jacobs LR. 2007. The Medicare approach: political choice and American institutions. J. Health Polit. Policy Law 32:159-86
40. Jacobs L, Skocpol T. 2010. Health Care Reform and American Politics: What Every American Needs to Know. New York: Oxford Univ. Press
41. Jasanoff S. 1990. The Fifth Branch: Science Advisors as Policymakers. Cambridge, MA: Harvard Univ. Press
42. Kleinman A. 2008. Catastrophe and caregiving: the failure of medicine as an art. Lancet 371:22-23
43. Lieberman E. 2009. Boundaries of Contagion: How Ethnic Politics Have Shaped Government Responses to AIDS. Princeton, NJ: Princeton Univ. Press
44. Maor M. 2011. Organizational reputations and the observability of public warnings in 10 pharmaceutical markets. Governance 24(3):557-82
45. MarksH. 1997. The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990. New York: Cambridge Univ. Press
46. Marmor T. 2000. The Politics of Medicare. New Brunswick, NJ: Transaction. 2nd ed.
47. Massard da Fonseca E. 2011. Reforming pharmaceutical regulation: a case study of generic drugs in Brazil. PhD thesis, Univ. Edinburgh
48. Moffitt SL. 2010. Promoting agency reputation through public advice: advisory committee use in the FDA. J. Polit. 3(72):880-93
49. Morgan JJ, Campbell AL. 2011. The Delegated Welfare State: Medicare, Markets, and the Governance of Social Policy. New York: Oxford Univ. Press
50. Morone J, Jacobs L, eds. 2007 Healthy, Wealthy and Fair: Health Care and the Good Society. New York: Oxford Univ. Press
51. Nussbaum N. 2011. Creating Capabilities: The Human Development Approach. Cambridge, MA: Harvard Univ. Press
52. Oberlander J. 2003. The Political Life of Medicare. Chicago: Univ Chicago Press
53. Parthasarathy S. 2007. Building GeneticMedicine: Breast Cancer, Technology, and the Comparative Politics of Health Care. Cambridge, MA: MIT Press
54. Patashnik E. 2008. Reforms at Risk: What Happens After Major Policy Changes Are Enacted. Princeton, NJ: Princeton Univ. Press
55. Peterson MA. 2011. It was a different time: Obama and the unique opportunity for health care reform. Special Issue on Health Care Reform. J. Health Polit. Policy Law 36( June):429-36
56. Quadagno J. 2005. One Nation, Uninsured: Why the US Has No National Health Insurance. New York: Oxford Univ. Press
57. Quirk P. 1980. The Food and Drug Administration. In The Politics of Regulation, ed. JQ Wilson, pp. 191-235. Washington, DC: Brookings Inst.
58. Rodwin MA. 2011. Conflicts of Interest and the Future of Medicine: The United States, France and Japan. New York: Oxford Univ. Press
59. Rodwin VG, Sandier S. 1993. Health care under French national health insurance. Health Aff. 12(3):111-31
60. Rothman DJ. 1991. Strangers at the Bedside: A History of How Law and Bioethics Transformed Medical Decision Making. New York: Harper Collins
61. Schlesinger M. 2002. A loss of faith: the sources of reduced political legitimacy for the American medical profession. Milbank Q. 80(2):1-45
62. Schlesinger M, Mitchell S, Elbel B. 2002. Voices unheard: barriers to the expression of dissatisfaction with health plans. Milbank Q. 80(4):709-55
63. Sackett DL, Torrance GW. 1978. The utility of different health states as perceived by the general public. J. Chronic Dis. 31(11):697-704
64. Sen A. 1999. Development as Freedom. New York: Oxford Univ. Press
65. Shavers VL, BrownML. 2002. Racial and ethnic disparities in the receipt of cancer treatment. J. Natl. Cancer Inst. 94(5):334-57
66. Skocpol T. 1992. Protecting Soldiers and Mothers: The Political Origins of Social Policy in the United States. Cambridge, MA: Harvard Univ. Press
67. Starr P. 1982. The Social Transformation of American Medicine. New York: Basic Books
68. Steinmo S, Watts J. 1995. It's the institutions, stupid: why comprehensive national health insurance always fails in America. J. Health Polit. Policy Law 20(2):329-72
69. Tolleson-Rinehart S, Peterson MA, eds. 2010. Health Politics and Policy, Vol. 4. London: Sage
70. Volden C. 2006. States as policy laboratories: emulating success in the Children's Health Insurance Program. Am. J. Polit. Sci. 50(2):294-312
71. Warren E, Tyagi AW. 2007. The Two-Income Trap. New York: Basic Books World Bank. 2010. World development indicators, 2010. Washington, DC: World Bank. http://data. worldbank.org/data-catalog/world-development-indicators?cid= GPD-wdi-2010